-
GLP-1R agonists disclosed in Shanghai Yidi Biotechnology patent
15 Sep 2025 22:44 GMT
-
Biotechnology patents: EPO practice and expert exchange
12 Sep 2025 13:50 GMT
… with its member states on biotechnology patents. The event brought together EPO … is facing increasing competition in biotechnology patent filings from the US and …
-
New indazoles disclosed in Nova Biotechnology patent
02 Sep 2025 15:17 GMT
-
[Event] Pharma & Biotech Patent Litigation USA - October 14th - 15th, New York, NY
21 Aug 2025 22:46 GMT
… inaugural Forum on Pharma & Biotech Patent Litigation USA and garner a …
-
Shenzhen Zhongge Biotechnology patents new PARP-7 inhibitors
30 May 2025 23:02 GMT
Cancer
Shenzhen Zhongge Biotechnology Co. Ltd. has disclosed protein mono-ADP-ribosyltransferase TIPARP (PARP-7; ARTD14) inhibitors reported to be useful for the treatment of inflammatory disorders, immunological disorders, viral infections and cancer.
…
-
New Mpro inhibitors revealed in Vir Biotechnology patent
10 Apr 2025 18:52 GMT
Infection
Work at Vir Biotechnology Inc. has led to the identification of 3C-like proteinase (3CLpro; Mpro; nsp5) (SARS-CoV-2; COVID-19 virus) inhibitors reported to be useful for the treatment of SARS-CoV-2 infections (COVID-19).
BioWorld Science …
-
Holista CollTech sues US company in biotech patent dispute
04 Apr 2025 09:17 GMT
-
Shenzhen Zhongge Biotechnology patents AMP-activated protein kinase α1β1γ1 activators
28 Mar 2025 21:58 GMT
Nephrology
Shenzhen Zhongge Biotechnology Co. Ltd. has synthesized AMP-activated protein kinase α1β1γ1 activators reported to be useful for the treatment of acute kidney injury, alopecia, chronic kidney disease, diabetes type 2, diabetic nephropathy, …
-
New KIF18A inhibitors disclosed in Shanghai Apeiron Biotechnology patent
11 Mar 2025 23:24 GMT
Cancer
Shanghai Apeiron Biotechnology Co. Ltd. has divulged kinesin-like protein KIF18A inhibitors reported to be useful for the treatment of cancer, inflammatory disorders and Kartagener syndrome (primary ciliary dyskinesia).
BioWorld Science Cancer …
-
AMP-activated protein kinase α1β1γ1 activators disclosed in Shenzhen Zhongge Biotechnology patent
18 Feb 2025 17:23 GMT
Nephrology
Shenzhen Zhongge Biotechnology Co. Ltd. has divulged AMP-activated protein kinase α1β1γ1 activators reported to be useful for the treatment of acute kidney injury, alopecia, chronic kidney disease, type 2 diabetes, diabetic nephropathy, …